FDA
No application listedNo application naming CJC-1295 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDACJC-1295 + Ipamorelin: blend, components and literature
A catalog item that supplies CJC-1295 without DAC and ipamorelin together in one vial. The single compounds are listed separately.
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is CJC-1295 + Ipamorelin?
A catalog item that supplies CJC-1295 without DAC and ipamorelin together in one vial. The single compounds are listed separately.
No formulation-level literature is listed. Each component's page lists its own studies. PubMed returns 11 records that mention every component in the title or abstract (checked 5 October 2026). This is a count of papers that name the components, not a count of studies of the combination.
Which compounds does CJC-1295 + Ipamorelin contain?
What is the regulatory status of each component?
CJC-1295 no DAC
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names CJC-1295 as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "CJC-1295". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.2.4The WADA 2026 Prohibited List, in force 1 January 2026 names CJC-1295 under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026Ipamorelin
FDA
No application listedNo application naming ipamorelin as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDAEMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names ipamorelin as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "ipamorelin". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Named, S2.2.4The WADA 2026 Prohibited List, in force 1 January 2026 names ipamorelin under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport.
WADA Prohibited List 2026The blend itself was not looked up as a product in the regulator databases; the component records above apply to the single compounds.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05; citations read from PubMed 2026-10-05.